- Published at
- by zacks.com
neutral
neutral
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals
Alcon, Glaukos and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog.
News for Glaukos Corporation (GKOS)
- Published at
- by economictimes.indiatimes.com
mixedmixedThe next big market boom? Mizuho analysts say baby boomers’ spending, not AI, will be a silver tsunami, to unlock a $1 trillion opportunity
Mizuho Financial Group analysts reveal that the spending power of America's aging population, particularly those aged 75 and above, will significantly impact the market, unlocking a $1 trillion opportunity, termed- Published at
- by businessinsider.com
mixedmixedThere's a $1 trillion opportunity brewing in the stock market — and it's got nothing to do with AI
Americans over the age of 75 are expected to grow their spending by more than $2 trillion in the next 10 years, according to Mizuho.- Published at
- by zacks.com
neutralneutralHere's Why You Should Retain Glaukos Stock in Your Portfolio
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.- Published at
- by gurufocus.com
positivepositiveRadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution
Topcon Healthcare, Inc., RadiusXR, and Glaukos Corporation (NYSE: GKOS) announced a new collaboration and the launch of RadiusXR's new wearable vision testing- Published at
- by insidermonkey.com
positivepositiveIs Glaukos Corporation (GKOS) the Best Medical Technology Stock to Buy According to Analysts?
We recently compiled a list of the 7 Best Medical Technology Stocks To Buy According To Analysts. In this article, we are going to take a look at where Glaukos Corporation (NYSE:GKOS) stands against ...- Published at
- by seekingalpha.com
positivepositiveFDA accepts Glaukos application for Epioxa for keratoconus (GKOS:NYSE)
Glaukos (GKOS) said the FDA has accepted its market application for its drug Epioxa for the treatment of the corneal disease keratoconus. Read more here.- Published at
- by gurufocus.com
positivepositiveGlaukos Announces FDA Acceptance of NDA Submission for Epioxa™
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal- Published at
- by seekingalpha.com
positivepositiveGlaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript
Glaukos Corporation (NYSE:GKOS) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsChris Lewis - Vice President, Investor...- Published at
- by zacks.com
positivepositiveGlaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of 6.98% and 4.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?- Published at
- by benzinga.com
neutralneutralThis NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - CervoMed (NASDAQ:CRVO), Glaukos (NYSE:GKOS)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...- Published at
- by zacks.com
neutralneutralWhat Analyst Projections for Key Metrics Reveal About Glaukos (GKOS) Q4 Earnings
Beyond analysts' top -and-bottom-line estimates for Glaukos (GKOS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.- Published at
- by zacks.com
neutralneutralHere's Why You Should Retain Glaukos Stock in Your Portfolio Now
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.- Published at
- by gurufocus.com
positivepositiveGlaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal- Published at
- by zacks.com
neutralneutralHere's Why You Should Add Glaukos Stock to Your Portfolio Now
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.- Published at
- by zacks.com
neutralneutralGlaukos Reaches 52-Week High: What's Driving the Stock's Rally?
Investors are optimistic about GKOS' strength in its product portfolio amid robust demand and expansion in new markets.- Published at
- by benzinga.com
positivepositiveGlaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday - Glaukos (NYSE:GKOS), Arqit Quantum (NASDAQ:ARQQ)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...- Published at
- by zacks.com
neutralneutralGlaukos Stock Down Despite NDA Submission of Epioxa to the FDA
GKOS announces New Drug Application submission for its Epioxa to the FDA.- Published at
- by investing.com
positivepositiveGlaukos president sells $498,715 in stock By Investing.com
Glaukos president sells $498,715 in stock- Published at
- by benzinga.com
positivepositiveThis Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Abercrombie & Fitch (NYSE:ANF), Glaukos (NYSE:GKOS)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...